Kodiak Sciences (KOD) Income from Continuing Operations (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Income from Continuing Operations came in at 522549000.0 in Q1 2026, down 780.19% YoY from 76824394.04 in Q1 2025, and down 35.73% on a QoQ basis from 384978000.0 in Q4 2025.
Powered by 
Analysis
Kodiak Sciences (KOD) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Income from Continuing Operations data on file, last reported at 522549000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 780.19% year-over-year to 522549000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1195583000.0 (down 512.96% YoY) and the FY2025 annual result came in at 558153000.0, down 31.98% from the prior year.
- Income from Continuing Operations eased to 522549000.0 in Q1 2026, from 384978000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 44772000.0 in Q1 2024 to a low of 522549000.0 in Q1 2026.
- A 5-year average of 121998529.41 and a median of 74502000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 84.3% — and 2026, when it sank 780.19%.
- Tracing KOD's Income from Continuing Operations over 5 years: stood at 71053000.0 in 2022, then dropped by 5.02% to 74621000.0 in 2023, then surged by 39.76% to 44949000.0 in 2024, then sank by 756.48% to 384978000.0 in 2025, then tumbled by 35.73% to 522549000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 522549000.0 (Q1 2026), 384978000.0 (Q4 2025), and 228013000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - | -65.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -65.58 Mn |
| Mar 31, 2026 | -58.14 Mn |
| Dec 31, 2025 | -56.70 Mn |
| Sep 30, 2025 | -61.44 Mn |
| Jun 30, 2025 | -54.27 Mn |
| Mar 31, 2025 | -57.47 Mn |
| Dec 31, 2024 | -44.05 Mn |
| Sep 30, 2024 | -43.92 Mn |
| Jun 30, 2024 | -45.03 Mn |
| Mar 31, 2024 | -42.70 Mn |
| Dec 31, 2023 | -59.48 Mn |
| Sep 30, 2023 | -49.97 Mn |
| Jun 30, 2023 | -80.15 Mn |
| Mar 31, 2023 | -71.00 Mn |
| Dec 31, 2022 | -71.05 Mn |
| Sep 30, 2022 | -77.00 Mn |
| Jun 30, 2022 | -90.58 Mn |
| Mar 31, 2022 | -95.70 Mn |
| Dec 31, 2021 | -93.05 Mn |
| Sep 30, 2021 | -67.50 Mn |